Charles Schwab’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $28.5M | Sell |
730,690
-5,775
| -0.8% | -$187K | ﹤0.01% | 1614 |
|
|
2026
Q1 | $24M | Buy |
736,465
+36,170
| +5% | +$1.16M | ﹤0.01% | 1637 |
|
|
2025
Q4 | $24.6M | Buy |
700,295
+2,587
| +0.4% | +$91.7K | ﹤0.01% | 1618 |
|
|
2025
Q3 | $18.3M | Sell |
697,708
-29,712
| -4% | -$886K | ﹤0.01% | 1782 |
|
|
2025
Q2 | $19.3M | Buy |
727,420
+15,523
| +2% | +$409K | ﹤0.01% | 1697 |
|
|
2025
Q1 | $17.2M | Sell |
711,897
-16,755
| -2% | -$530K | ﹤0.01% | 1711 |
|
|
2024
Q4 | $29.3M | Buy |
728,652
+13,055
| +2% | +$744K | 0.01% | 1468 |
|
|
2024
Q3 | $45.3M | Buy |
715,597
+44,122
| +7% | +$2.59M | 0.01% | 1189 |
|
|
2024
Q2 | $35.6M | Sell |
671,475
-167,509
| -20% | -$11M | 0.01% | 1297 |
|
|
2024
Q1 | $68.8M | Buy |
838,984
+63,285
| +8% | +$2.82M | 0.02% | 809 |
|
|
2023
Q4 | $14.4M | Buy |
775,699
+10,379
| +1% | +$136K | ﹤0.01% | 1794 |
|
|
2023
Q3 | $8.47M | Buy |
765,320
+505,578
| +195% | +$7.23M | ﹤0.01% | 1996 |
|
|
2023
Q2 | $4.21M | Buy |
259,742
+223,074
| +608% | +$4.67M | ﹤0.01% | 2301 |
|
|
2023
Q1 | $611K | Buy |
36,668
+7,702
| +27% | +$79.6K | ﹤0.01% | 2886 |
|
|
2022
Q4 | $272K | Hold |
28,966
| – | – | ﹤0.01% | 3137 |
|
|
2022
Q3 | $79K | Sell |
28,966
-15,500
| -35% | -$50.8K | ﹤0.01% | 3242 |
|
|
2022
Q2 | $129K | Sell |
44,466
-151,944
| -77% | -$376K | ﹤0.01% | 3270 |
|
|
2022
Q1 | $590K | Buy |
196,410
+19,084
| +11% | +$68.5K | ﹤0.01% | 3054 |
|
|
2021
Q4 | $816K | Buy |
177,326
+5,231
| +3% | +$29.3K | ﹤0.01% | 2983 |
|
|
2021
Q3 | $1.08M | Buy |
172,095
+556
| +0.3% | +$3.44K | ﹤0.01% | 2848 |
|
|
2021
Q2 | $1.03M | Buy |
171,539
+5,084
| +3% | +$30.2K | ﹤0.01% | 2922 |
|
|
2021
Q1 | $1.05M | Buy |
166,455
+11,372
| +7% | +$80K | ﹤0.01% | 2838 |
|
|
2020
Q4 | $874K | Sell |
155,083
-264
| -0.2% | -$1.6K | ﹤0.01% | 2816 |
|
|
2020
Q3 | $905K | Sell |
155,347
-6,131
| -4% | -$42.2K | ﹤0.01% | 2701 |
|
|
2020
Q2 | $1.17M | Sell |
161,478
-6,675
| -4% | -$44.3K | ﹤0.01% | 2580 |
|
|
2020
Q1 | $787K | Buy |
168,153
+3,203
| +2% | +$19.7K | ﹤0.01% | 2548 |
|
|
2019
Q4 | $1.32M | Buy |
164,950
+2,582
| +2% | +$18.8K | ﹤0.01% | 2524 |
|
|
2019
Q3 | $1.12M | Buy |
162,368
+14,021
| +9% | +$104K | ﹤0.01% | 2537 |
|
|
2019
Q2 | $1.23M | Buy |
148,347
+13,692
| +10% | +$117K | ﹤0.01% | 2507 |
|
|
2019
Q1 | $1.34M | Buy |
134,655
+5,473
| +4% | +$45.8K | ﹤0.01% | 2469 |
|
|
2018
Q4 | $989K | Buy |
129,182
+17,800
| +16% | +$213K | ﹤0.01% | 2543 |
|
|
2018
Q3 | $1.94M | Buy |
111,382
+19,282
| +21% | +$229K | ﹤0.01% | 2433 |
|
|
2018
Q2 | $875K | Buy |
+92,100
| New | +$613K | ﹤0.01% | 2618 |
|
Other funds holding VKTX
Charles Schwab's VKTX Position: Q2 2026 in Review
Charles Schwab reduced its Viking Therapeutics (VKTX) stake by 0.78% in Q2 2026, selling an estimated $187K and leaving 730,690 shares worth $28.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1614.
Charles Schwab first reported a position in VKTX in Q2 2018 and has held it in 33 quarters since. The position peaked at $68.8M in Q1 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.
- Charles Schwab held 730,690 shares of Viking Therapeutics worth $28.5M as of Q2 2026.
- Charles Schwab sold 5,775 Viking Therapeutics shares in Q2 2026, an estimated $187K.
- Viking Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1614 holding.
- Charles Schwab first reported a position in Viking Therapeutics in Q2 2018 and has held it in 33 quarters since.
- Charles Schwab's Viking Therapeutics position peaked at $68.8M in Q1 2024.
- 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.